Compositions and methods of nucleic acid-targeting nucleic acids

Inventors

May, Andrew Paul • Haurwitz, Rachel E. • DOUDNA, Jennifer A. • Berger, James M. • Carter, Matthew Merrill • Donohoue, Paul Daniel

Assignees

Caribou Biosciences Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12686865-B2

Patent

Publication Date

2026-07-21

Expiration Date


Abstract

This disclosure provides for compositions and methods for the use of nucleic acid-targeting nucleic acids and complexes thereof. Genome engineering can refer to altering the genome by deleting, inserting, mutating, or substituting specific nucleic acid sequences. The altering can be gene or location specific. Genome engineering can use nucleases to cut a nucleic acid thereby generating a site for the alteration. Engineering of non-genomic nucleic acid is also contemplated.

Core Innovation

The independent claim describes a method of delivering a donor polynucleotide to a target nucleic acid within a cell nucleus using a complex that includes a site-directed polypeptide fused to reverse transcriptase and an engineered single guide nucleic acid-targeting nucleic acid (NATNA). The engineered single guide NATNA comprises a spacer that specifically hybridizes to the target nucleic acid, a crRNA, a tracrRNA, and an RNA 3′ hybridizing extension comprising a reverse transcription template and a binding site for reverse transcriptase.

The site-directed polypeptide introduces a single-stranded break within the target nucleic acid, and reverse transcription produces DNA comprising the donor polynucleotide within the nucleus. Engineered single-guide variants, including architectures with RNA extensions or Csy4-binding sequences, retain cleavage activity for targeting and donor delivery. The background problem being addressed is not explicitly described in the patent text.

Claims Coverage

The claim coverage centers on one independent claim directed to donor polynucleotide delivery to a target nucleic acid within a cell nucleus, comprising three inventive features.

Complex comprising a site-directed polypeptide fused to a reverse transcriptase

The method contacts the cell with a complex comprising a site-directed polypeptide fused to a reverse transcriptase for donor-polynucleotide delivery.

Engineered single guide nucleic acid-targeting nucleic acid with an RNA 3′ hybridizing extension

The engineered single guide NATNA comprises a spacer that specifically hybridizes to the target nucleic acid, a crRNA, a tracrRNA, and an RNA 3′ hybridizing extension comprising a reverse transcription template and a binding site for reverse transcriptase.

Delivery of donor polynucleotide to a target nucleic acid in the nucleus

The site-directed polypeptide introduces a single-stranded break within the target nucleic acid, and reverse transcription within the nucleus delivers newly transcribed DNA comprising the donor polynucleotide to the nucleus of the cell.

The independent claim covers a complex combining a site-directed polypeptide fused to reverse transcriptase with an engineered guide nucleic acid containing an RNA extension to deliver donor-polynucleotide-containing DNA to a target nucleic acid in a cell nucleus.

Stated Advantages

Many engineered single-guide NATNA variants retain Cas9 cleavage activity, including variants with Csy4-binding sequences.

Documented Applications

Genome engineering and delivery of a donor polynucleotide to a target nucleic acid within the nucleus of a cell.

Induction of changes to disease-related pathway protein levels or morphological, metabolic, or structural changes in the cell.

Stable genomic cell tagging for cell-lineage tracking.

Genomic barcoding.

Therapeutic cell engineering.

CRISPR-based target enrichment.

Off-target binding-site sequencing.

Sequence-variant detection.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.